This has resulted in the recent formulation and FDA approval of osimertinib, a compound capable of inhibiting T790M mutant EGFR.9 These lessons in NSCLC have served as a critical example of the need for biomarkers to drive application of kinase inhibitors to EGFR. This evidence concerns the gene EGFR and non-small cell lung carcinoma.